The vaso‐occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management
| Autor: | Deepika S. Darbari, Samir K. Ballas, Vivien A. Sheehan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Anemia Clinical Decision-Making Pain Anemia Sickle Cell Disease Diagnosis Differential 03 medical and health sciences 0302 clinical medicine Antisickling Agents Risk Factors Humans Pain Management Medicine media_common.cataloged_instance European union Disease management (health) Intensive care medicine Pain Measurement media_common business.industry Chronic pain Disease Management Hematology General Medicine Prognosis medicine.disease Pathophysiology Treatment Outcome 030220 oncology & carcinogenesis Neuropathic pain Hyperalgesia Disease Susceptibility medicine.symptom business Biomarkers 030215 immunology |
| Zdroj: | European Journal of Haematology. 105:237-246 |
| ISSN: | 1600-0609 0902-4441 |
| DOI: | 10.1111/ejh.13430 |
| Popis: | Early diagnosis, treatment, and prevention of a vaso-occlusive crisis (VOC) are critical to the management of patients with sickle cell disease. It is essential to differentiate between VOC-associated pain and chronic pain, hyperalgesia, neuropathy, and neuropathic pain. The pathophysiology of VOCs includes polymerization of abnormal sickle hemoglobin, inflammation, and adhesion. Hydroxyurea, L-glutamine, crizanlizumab, and voxelotor have been approved by the US Food and Drug Administration for reducing the frequency of VOCs; the European Medicines Agency has approved only hydroxyurea. Other novel treatments are in late-stage clinical development in both the United States and the European Union. The development of agents for prevention and treatment of VOCs should be driven by our understanding of its pathophysiology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |